



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: UCKUN ET AL. Examiner: UNKNOWN
Serial No.: 10/715,773 Group Art Unit: 1614
Filed: NOVEMBER 17, 2003 Docket: 12152.76USC2
Confirmation No.: 8890
Title: THERAPEUTIC COMPOUNDS

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 March 29, 2005.

By: 

Name: KATE GANNER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 4 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

By: 

Name: John L. Haack

Reg. No.: 36,154

JHaack:JKS:PLSklg



10/715,773

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	UCKUN ET AL.	Examiner:	UNKNOWN
Serial No.:	10/715,773	Group Art Unit:	1614
Filed:	NOVEMBER 17, 2003	Docket No.:	12152.76USC2
Title:	THERAPEUTIC COMPOUNDS		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 March 29, 2005.

By:

Name:

Kate Gannon
Kate Gannon

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: March 29, 2005



John L. Haack

Reg. No. 36,154
JLH:JKS:PLSklg



FORM 1739* INFO
O I P E
MAR 31 2005
PATENT & TRADEMARK OFFICE

[illegible]

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/00202	01/06/2000	PCT				
	WO 00/51587	09/08/2000	PCT				

		Chen, C. et al., "Pharmacokinetics and Biologic Activity of the Novel Mast Cell Inhibitor, 4-(3'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in Mice," <i>Pharmaceutical Research</i> , Vol. 16, No. 1, pp. 117-122 (1999)
		Uckun, F. et al., "Article 224 - Janus Kinase (JAK)-3 in Mast Cells as a Mediator of Immediate Hypersensitivity Reactions and Anaphylaxis," <i>The Journal of Allergy and Clinical Immunology</i> , Vol. 103, No. 1, 14 pages (January 1999, part 2)

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	